Lates News

Novo Nordisk (NVO.N) announced that all results from early trials show that the company's experimental drug, Amycretin, can help overweight and obese adults lose up to 24% of their body weight. Novo Nordisk is now preparing to begin late-stage studies next year. The company stated that the main side effects of this drug are gastrointestinal symptoms, with a similar occurrence rate to other recent weight-loss medications.